Several studies in our lab focus on identifying biomarkers of language development in young children at risk for severe language impairment, including infant siblings of children with autism spectrum disorders, and genetic disorders such as Fragile X syndrome and Down syndrome. Biomarkers identified through these studies could be used as objective measures of language prognosis, treatment monitoring during clinical trials, and development of effective therapies.